| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088) | Sumithira Vasu | 2022-06-30 |
| Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children (NCT04325841) | Beijing Boren Hospital | 2022-03-24 |
| A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents (NCT05334823) | Chongqing Precision Biotech Co., Ltd | 2022-01-26 |
| Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia (NCT04996160) | Tanja Andrea Gruber | 2021-07-09 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia (NCT04526795) | M.D. Anderson Cancer Center | 2021-04-09 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (NCT04752163) | M.D. Anderson Cancer Center | 2021-03-25 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer (NCT03739606) | City of Hope Medical Center | 2020-10-20 |
| Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML (NCT04139434) | Newave Pharmaceutical Inc | 2020-07-06 |
| Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia (NCT04562792) | Children's Mercy Hospital Kansas City | 2020-05-08 |
| Study of Anti-CD22 CAR-T Cells Treating Leukemia Children (NCT04340167) | Beijing Boren Hospital | 2020-05-01 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents (NCT04888468) | Chongqing Precision Biotech Co., Ltd | 2019-11-05 |
| Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias (NCT04000698) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2019-10-15 |
| Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia (NCT03512405) | City of Hope Medical Center | 2019-08-02 |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03670966) | Fred Hutchinson Cancer Center | 2019-07-10 |
| Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT04012879) | Chinese PLA General Hospital | 2019-05-01 |
| Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL (NCT03349281) | Julio Barredo, MD | 2019-03-25 |
| Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia (NCT03575325) | H. Lee Moffitt Cancer Center and Research Institute | 2018-10-11 |
| CART22 Alone or in Combination With huCART19 for ALL (NCT03620058) | University of Pennsylvania | 2018-09-27 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia (NCT03576547) | M.D. Anderson Cancer Center | 2018-06-26 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia (NCT03519984) | University of Southern California | 2018-05-09 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921) | Fred Hutchinson Cancer Center | 2018-02-23 |
| Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (NCT03147612) | M.D. Anderson Cancer Center | 2018-02-08 |
| Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia (NCT03094611) | M.D. Anderson Cancer Center | 2017-11-30 |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia (NCT03263572) | M.D. Anderson Cancer Center | 2017-11-29 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034) | Fred Hutchinson Cancer Center | 2017-10-24 |
| Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies (NCT03241940) | Stanford University | 2017-10-20 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (NCT03136146) | M.D. Anderson Cancer Center | 2017-08-09 |
| Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia (NCT03132454) | M.D. Anderson Cancer Center | 2017-07-25 |
| Personalized NK Cell Therapy in CBT (NCT02727803) | M.D. Anderson Cancer Center | 2016-05-19 |
| ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome (NCT02392572) | M.D. Anderson Cancer Center | 2015-11-03 |
| High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NCT02551718) | University of Washington | 2015-09-11 |
| Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (NCT02143414) | National Cancer Institute (NCI) | 2015-06-30 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD (NCT02220985) | Fred Hutchinson Cancer Center | 2015-03-23 |
| Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT02199184) | M.D. Anderson Cancer Center | 2015-01-14 |
| Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (NCT02146924) | City of Hope Medical Center | 2014-10-16 |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia (NCT01865617) | Fred Hutchinson Cancer Center | 2013-05-22 |
| NK Cells in Cord Blood Transplantation (NCT01619761) | M.D. Anderson Cancer Center | 2013-05-03 |
| Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma (NCT01658007) | Children's Hospital Medical Center, Cincinnati | 2012-08-01 |
| Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia (NCT01620216) | OHSU Knight Cancer Institute | 2012-05-11 |